• 中国资本市场开放出大招 跨境证券投资更便利 2019-10-13
  • 世卫将“游戏障碍”列为新疾病 哪些症状可被确诊? 2019-10-13
  • 景区去门票化积弊短期难除 如何摆脱门票依赖? 2019-10-08
  • 东风路老旧小区欲华丽变身 微改造项目勘察设计已招标 ——凤凰网房产广州 2019-10-08
  • 翔龙无人机服役后首次曝光,大幅提升空军情报收集能力 2019-09-19
  • 证监会去年对外公开监管信息14560条 2019-09-19
  • 人民网欧洲中心分社记者报道集 2019-09-06
  • 图解:短视频平台频遭约谈敲响警钟,野蛮生长要不得! 2019-09-06
  • 中考期间广州部分公交线路有调整 2019-09-01
  • 减肥必备!这十种食物饱口福还能吃出好身材 2019-09-01
  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>公司动态>Actavis收购Warner Chilcott

    江苏11选五开奖结果: Actavis收购Warner Chilcott

    Actavis2013年5月21日 8:57 点击:1645

    时时彩网络平台 www.qlgr.net Actavis  爱尔兰Warner Chilcott


    北京时间5月20日晚间消息,全球领先的仿制药制造商Actavis Inc在本周一对外表示,已经敲定了一项协议,将以50亿美元的股权价格收购爱尔兰制药商Warner Chilcott PLC。早前市场曾普遍猜测,ActavisInc曾是多家药企竞相收购的对象。

    据了解,Warner Chilcott的股东将获得0.16股合并后公司的股权。如果基于Actavis在上周五每股125.5美元的收盘价计算,那么Actavis的每股收购价将达到20.08美元。

    如果与Warner Chilcott在今年5月9日每股15.01美元的收购价相比,Actavis的收购价存在34%的溢价。因为在此后一天,双方就对外表示,正在就收购事宜展开磋商。Warner Chilcott在上周五收于每股19.19美元,从而使得收购价的溢价幅度不足5%。

    //www.actavis.com/en/media+center/warner_chilcott_acquisition.htm

    Actavis to Acquire Warner Chilcott to Create Premier $11 Billion Revenue Global Specialty Pharmaceutical Company
    - Top 3 U.S. ~$3.0 Billion Revenue Specialty Brand Business -
    - Expands Portfolio and Pipeline in Core Areas of Women's Health and Urology -
    - Adds Gastroenterology and Dermatology Franchises and Infrastructure -
    - Stronger Commercial Presence to Support Expanded Brand Pipeline -
    - Immediately Accretive With Opportunities for Substantial Operational Synergies and Tax Savings -
    - Combination Expected to Generate Strong EBITDA and Cash from Operations -
    - All Stock Transaction Further Enables Rapid Deleveraging -
    - Anticipate Closing by Year End 2013, Pending Approvals -

    PARSIPPANY, N.J. and DUBLIN, May 20, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) and Warner Chilcott plc (NASDAQ: WCRX) today announced they have entered into a definitive agreement under which Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion.  If successfully completed, the transaction will create a leading global specialty pharmaceutical company with approximately $11 billion in combined annual revenue, and the third-largest U.S. specialty pharmaceutical company with approximately $3 billion in annual revenues focused on core therapeutic categories of Women's Health, Gastroenterology, Urology and Dermatology.  The proposed transaction has been unanimously approved by the Boards of Directors of Actavis, Inc. and Warner Chilcott plc, and is supported by the management teams of both companies.

    "We have set as our strategic corporate objective to build a leading global specialty pharmaceutical company," said  Paul Bisaro, President and CEO of Actavis.  "The combination of Actavis and Warner Chilcott creates a strong specialty brand portfolio focused in therapeutic categories with strong growth potential, and is supported by a deep pipeline of development programs. The combination is commercially and financially compelling, and reshapes the specialty pharmaceutical universe by creating a powerful global competitor.  It creates a company with an exceptionally strong balance sheet, coupled with a favorable tax structure to support future growth.

    "Commercially, this transaction is unique in the combination of the complementary strengths of our two companies," Bisaro added.  "The combination will enhance the value of each company's portfolio and provides a substantial foundation to support the successful launch of new products over the next several years, particularly in Women's Health, including Minastrin 24 Fe, Esmya, metronidazole vaginal gel 1.5%, the progestin-only contraceptive patch and other women's health products in development from the recent acquisition of Uteron Pharma SA. It also provides an expanded portfolio of specialty products that have the potential to be commercialized in key markets outside of North America."
     

    "The Warner Chilcott team has built a powerful specialty brands business with a strong pipeline, and this compelling transaction brings together two complementary organizations with the potential to create even more value for shareholders," said  Roger Boissonneault, President and CEO of Warner Chilcott. " Paul Bisaro and his team have been executing on their vision to build a global and diverse company at the forefront of the specialty pharmaceutical industry, and the addition of Warner Chilcott should enhance the ability of the combined company to successfully execute that vision, and accelerate Actavis' evolution."

    At the close of the transaction (the "Effective Date"), which is expected by year-end 2013, Actavis and Warner Chilcott will be combined under a new company incorporated in Ireland, where Warner Chilcott is currently incorporated.  The newly created company, which is expected to be called Actavis plc, or a variant thereof ("New Actavis"), will be led by the current Actavisleadership team. 

    Under the terms of the Transaction Agreement, at closing Warner Chilcott shareholders will receive 0.160 shares of New Actavis for each Warner Chilcott share they own, which equates to a value of $20.08 per Warner Chilcott share based on Actavis' closing share price of $125.50 on May 17, 2013. This represents a 43 percent premium compared to Warner Chilcott's volume-weighted average trading price of $14.00 for the 30 day trading period ending on May 9, 2013 (the day before Warner Chilcott disclosed it was engaged in preliminary discussions with Actavis) and a 34 per cent premium to the Warner Chilcott closing share price onMay 9, 2013 of $15.01. Based on the closing prices of Actavis shares and Warner Chilcott shares on May 9, 2013 of $106.81 and$15.01 each respectively, the value of the consideration payable per Warner Chilcott share would be $17.09 which would represent a premium of 14 per cent over the Warner Chilcott closing share price on such date.

    The transaction is expected to be tax-free, for U.S. federal income tax purposes, to Warner Chilcott shareholders.  Actavisshareholders will receive one share of New Actavis for each Actavis share they own upon closing. The transaction will be taxable, for U.S. federal income tax purposes, to Actavis shareholders.

    Immediately after the close of the transaction, Warner Chilcott shareholders are expected to own approximately 23 percent of New Actavis.  Shares of New Actavis are expected to trade on the New York Stock Exchange under the ticker symbol ACT.
     

    Expanded Specialty Portfolio in Four Therapeutic Categories

    • The combined company will have a stronger foundation to market a complementary product portfolio in key specialty areas:
      • In Women's Health, with eight products including contraceptives, infertility treatments and hormone therapy products; 
      • In Urology, with six marketed products for the treatment of overactive bladder, testosterone replacement, prostate cancer and benign prostatic hyperplasia (BPH);
      • In Gastroenterology, with two marketed products for the treatment of ulcerative colitis;
      • In Dermatology, with one marketed product and the expected commercial launch of a newly approved product in July 2013; and,
      • A R&D portfolio of more than 25 products in various stages of development, including 15 candidates in Women's Health.
    • The combined company will have the ability to grow through additional in-licensing opportunities within its key therapeutic categories.
    • The combination will also provide the opportunity to introduce a broader portfolio of new products in Actavis' expanded global footprint.

    Financially Compelling

    • The Directors of Actavis and Warner Chilcott believe that the combined company will have annual revenues of approximately$11 billion.
    • The combination of Actavis and Warner Chilcott will result in Specialty Brand sales comprising approximately 25 percent of total combined company 2013 revenues, when compared to approximately 7 percent for standalone Actavis.
    • The transaction is expected to be more than 30 percent accretive to Actavis non-GAAP earnings per share in 2014, including anticipated synergies.
    • More than $400 million in after-tax operational synergies and related cost reductions and tax savings are anticipated. The majority of savings are expected to be realized in 2014, with full effect during 2015. The majority of these are operational and this estimate excludes any revenue, manufacturing or interest rate synergies or savings.
    • The combination is expected to generate strong operating cash flow which would further enable the combined company to rapidly delever the balance sheet to below 3.0x debt to adjusted EBITDA at close.

    Transaction Approval Process    

    The acquisition of Warner Chilcott by New Actavis will be effected by means of a "scheme of arrangement" under Irish law pursuant to which New Actavis will acquire all of the outstanding shares of Warner Chilcott from Warner Chilcott shareholders in exchange for shares to be issued by New Actavis (the "Acquisition"). The Acquisition will be subject to the terms and conditions to be set forth in the scheme of arrangement document to be delivered to Warner Chilcott shareholders.

    To become effective, the Scheme of Arrangement will require, among other things, the approval of a majority in number ofWarner Chilcott shareholders, present and voting either in person or by proxy at a special Warner Chilcott shareholder meeting, representing 75 percent or more in value of Warner Chilcott shares held by such holders.  Following the requisite Warner Chilcott shareholder approval being obtained, the sanction of the Irish High Court is also required.

    In addition, the transaction must be approved in a special meeting by shareholders holding a majority of the outstanding Actaviscommon shares.  The transaction, which is unanimously recommended by the Boards of Directors of both companies, is also subject to customary closing conditions, including the receipt of certain regulatory approvals, as more particularly set out in Appendix III of this announcement.

    Conference Call    

    Actavis and Warner Chilcott will host a conference call to discuss the transaction today at 8:00 AM EDT.  The number to call from within the United States is 877-251-7980, passcode 73978818.  From international locations, the conference call can be accessed at 706-643-1573 using the same passcode.  The call will also be webcast and can be accessed through the companies' websites at www.wcrx.com and www.actavis.com.  To access the slides go to Actavis' Investor Relations Web site at//ir.actavis.com, or directly at //www.videonewswire.com/event.asp?id=94188   A replay of the conference call will also be available by calling 800-585-8367 in the U.S. or 404-537-3406 outside of the U.S., passcode 73978818.
     

    About Actavis, Inc.

    Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.  Actavis has global headquarters in Parsippany, New Jersey, USA. 

    Operating as Actavis Pharma, Actavis develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries.  Actavis Specialty Brands is Actavis' global branded specialty pharmaceutical business focused in the Urology and Women's Health therapeutic categories.  Actavis Specialty Brands also has a portfolio of five biosimilar products in development in Women's Health and Oncology.  Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.

    For press release and other company information, visit Actavis' Web site at //www.actavis.com.

    About Warner Chilcott

    Warner Chilcott is a leading specialty pharmaceutical company currently focused on the Women's Healthcare, Gastroenterology, Urology and Dermatology segments of the branded pharmaceuticals market, primarily in North America. Warner Chilcott is a fully integrated company with internal resources dedicated to the development, manufacture and promotion of its products.

    About New Actavis

    New Actavis is a private limited company incorporated in Ireland, solely for the purpose of effecting the transaction. Prior to the Effective Date, New Actavis shall be converted, pursuant to the Irish Companies Acts, to a public limited company. To date, New Actavis has not conducted any activities other than those incidental to its formation and the execution of the Transaction Agreement.

    At closing under the Transaction Agreement, New Actavis will acquire, pursuant to a "scheme of arrangement" under Irish law, all of the outstanding shares of Warner Chilcott in exchange for shares to be issued by New Actavis (the "Acquisition"). Warner Chilcott shareholders will receive 0.160 shares of New Actavis for each Warner Chilcott share they own.

    Simultaneously with and conditioned on the concurrent consummation of the Acquisition, a wholly owned indirect subsidiary of New Actavis will merge with and into Actavis, the separate corporate existence of the wholly-owned subsidiary will cease andActavis will continue as the surviving corporation. At the Effective Date, all Actavis common shares will be cancelled and will automatically be converted into the right to receive New Actavis Shares on a one-for-one basis.

    At and as of the Effective Date, it is expected that New Actavis will be a publicly traded company listed on the NYSE under the ticker symbol ACT.

    (来源: Actavis )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • 中国资本市场开放出大招 跨境证券投资更便利 2019-10-13
  • 世卫将“游戏障碍”列为新疾病 哪些症状可被确诊? 2019-10-13
  • 景区去门票化积弊短期难除 如何摆脱门票依赖? 2019-10-08
  • 东风路老旧小区欲华丽变身 微改造项目勘察设计已招标 ——凤凰网房产广州 2019-10-08
  • 翔龙无人机服役后首次曝光,大幅提升空军情报收集能力 2019-09-19
  • 证监会去年对外公开监管信息14560条 2019-09-19
  • 人民网欧洲中心分社记者报道集 2019-09-06
  • 图解:短视频平台频遭约谈敲响警钟,野蛮生长要不得! 2019-09-06
  • 中考期间广州部分公交线路有调整 2019-09-01
  • 减肥必备!这十种食物饱口福还能吃出好身材 2019-09-01
  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 湖北11选5投注app 福建体彩11玩法 彩票11选五开奖 极速时时彩有猫腻吗 AG赌场 博聚是什么意思 8加2双色球中6个红球 新疆十一选五和值跨度速查表 排列五综合走势图排列五走势图综合版 超级大乐透第15067期 安徽十一选五走势图 淘宝双色球彩票大奖 河南快赢481专家推荐 一波中特公开版 北京pk10全天7吗计划